Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

HEPA

Hepion Pharmaceuticals Inc

Dec 13 • 04:00PM ET

0.5900

Dollar change -0.0300
Percentage change -4.84	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD VRTX BIIB MDGL EXEL IONS AKRO NBIX ARWR LLY

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.39	Insider Own	0.09%	Shs Outstand	6.96M	Perf Week	-4.81%
Market Cap	3.91M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	6.95M	Perf Month	-8.60%
Income	-22.70M	PEG	-	EPS next Q	-	Inst Own	7.84%	Short Float	0.68%	Perf Quarter	-13.24%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	0.99%	Short Ratio	1.07	Perf Half Y	-46.80%
Book/sh	-0.30	P/B	-	EPS next Y	-	ROA	-158.12%	Short Interest	0.05M	Perf Year	-85.18%
Cash/sh	0.23	P/C	2.61	EPS next 5Y	-	ROE	-288.27%	52W Range	0.48 - 4.22	Perf YTD	-81.79%
Dividend Est.	-	P/FCF	-	EPS past 5Y	63.67%	ROI	-	52W High	-86.02%	Beta	1.66
Dividend TTM	-	Quick Ratio	1.30	Sales past 5Y	0.00%	Gross Margin	-	52W Low	23.51%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	1.30	EPS Y/Y TTM	64.94%	Oper. Margin	-	RSI (14)	42.04	Volatility	13.24% 9.80%
Employees	22	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	3.00	Target Price	22.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	73.59%	Payout	-	Rel Volume	0.42	Prev Close	0.62
Sales Surprise	-	EPS Surprise	-17.54%	Sales Q/Q	-	Earnings	-	Avg Volume	43.97K	Price	0.59
SMA20	-8.63%	SMA50	-9.30%	SMA200	-47.61%	Trades		Volume	18,602	Change	-4.84%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-20-20	Resumed	ROTH Capital	Buy	$14

Dec-11-24 08:00AM	Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. (GlobeNewswire) -7.15%
Dec-05-24 08:30AM	Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study Group (GlobeNewswire)
Dec-02-24 08:00AM	Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B (GlobeNewswire) -5.69%
Nov-11-24 08:00AM	Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger (GlobeNewswire) +7.64%
Sep-04-24 09:25AM	Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger (GlobeNewswire)
08:00AM	Loading…
Jul-22-24 08:00AM	Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement (GlobeNewswire) -17.65%
May-21-24 09:52PM	HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q1 2024 (InvestorPlace)
Apr-22-24 08:56AM	Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today? (InvestorPlace) -29.85%
Apr-19-24 04:30PM	Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trial (GlobeNewswire)
Apr-16-24 11:52PM	HEPA Stock Earnings: Hepion Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace) -6.42%
Mar-06-24 08:30AM	Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell (GlobeNewswire) -11.92%
Feb-16-24 08:00AM	Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds (GlobeNewswire) -5.19%
Jan-03-24 05:15PM	Hepion Pharmaceuticals to Present at NASH-TAG 2024 (GlobeNewswire)
Dec-07-23 08:00AM	Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes (GlobeNewswire) -5.56%
Nov-28-23 04:15PM	Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit (GlobeNewswire)
04:05PM	Loading…
Nov-13-23 04:05PM	Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease (GlobeNewswire) +13.82% -15.33%
Nov-10-23 08:50AM	Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 'ALTITUDE-NASH' Liver Function Trial of Rencofilstat (GlobeNewswire)
Oct-25-23 08:30AM	Hepion Pharmaceuticals' Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model (GlobeNewswire)
Sep-29-23 08:00AM	Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules (GlobeNewswire)
Sep-21-23 04:05PM	Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference (GlobeNewswire) -7.89%
08:00AM	New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals Rencofilstat in Cancer Screening Program (GlobeNewswire)
Sep-19-23 09:00AM	Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer (GlobeNewswire)
Sep-18-23 11:01AM	Insider Buying: Robert Foster Acquires 1,600 Shares of Hepion Pharmaceuticals Inc (GuruFocus.com) +6.10%
Sep-14-23 08:45AM	Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Sep-06-23 04:30PM	Hepion Pharmaceuticals Announces Management Changes (GlobeNewswire) -10.71%
Jun-15-23 04:45PM	Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress 2023 (GlobeNewswire)
08:22AM	Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ASCEND-NASH Trial of Rencofilstat (GlobeNewswire)
May-24-23 04:45PM	Hepion Pharmaceuticals to Highlight AI-POWR at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical Sciences (GlobeNewswire) -12.20% -17.30%
May-22-23 07:00AM	Hepion Pharmaceuticals Phase 2 ALTITUDE-NASH Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers (GlobeNewswire) +118.40%
May-19-23 04:05PM	Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ALTITUDE-NASH Liver Function Trial of Rencofilstat (GlobeNewswire)
11:15AM	Loading…
May-10-23 11:15AM	Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split (GlobeNewswire) -17.32%
Apr-17-23 04:15PM	Hepion Pharmaceuticals to Present Data on Synergistic Effects of Rencofilstat with Anti-PD1 at AACR 2023 (GlobeNewswire)
Mar-30-23 08:45AM	Hepion Pharmaceuticals Expands SAB with Appointments of Four Liver Disease KOLs (GlobeNewswire) +8.79%
Mar-16-23 04:10PM	Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug Development (GlobeNewswire)
Mar-02-23 04:15PM	Hepion Pharmaceuticals to Deliver Updates on Ongoing Phase 2 NASH Clinical Program with Rencofilstat at 6th Global NASH Congress (GlobeNewswire) +9.31%
09:15AM	EPO Decision to Grant European Patent for Rencofilstat Further Strengthens Hepions Patent Portfolio (GlobeNewswire)
Feb-09-23 04:15PM	Hepion Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell on February 10, 2023 (GlobeNewswire) -5.74% +7.04%
Jan-18-23 09:15AM	Anti-Cancer Potential of Rencofilstat Expanded with Results from Preclinical Multiple Myeloma Studies (GlobeNewswire) -24.60%
Jan-10-23 04:15PM	Presentation of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors (GlobeNewswire) +35.42%
Jan-09-23 08:00AM	Hepion Pharmaceuticals Receives $3.2 Million in Aggregate Non-Dilutive Funding (GlobeNewswire)
Jan-05-23 04:15PM	Hepion Pharmaceuticals to Present Phase 2a Rencofilstat Multiomics Data at NASH-TAG 2023 (GlobeNewswire) +25.40%
Dec-05-22 04:30PM	Hepion Pharmaceuticals, Inc. Granted 180-day Extension by Nasdaq to Meet the Minimum Bid Price Requirements (GlobeNewswire)
09:00AM	Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 ALTITUDE-NASH Liver Function Trial (GlobeNewswire)
Nov-07-22 08:00AM	Hepion Pharmaceuticals to Present Rencofilstats Poly-Indication Potential at the 6th Annual Antifibrotic Drug Development Summit (GlobeNewswire) -5.92%
Nov-04-22 08:30AM	Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock (GlobeNewswire) -23.98%
Nov-02-22 08:00AM	Hepion Pharmaceuticals to Present Two Posters at Upcoming AASLD The Liver Meeting® 2022 (GlobeNewswire)
Oct-26-22 08:00AM	Hepion Pharmaceuticals Announces Publication of Phase 2a AMBITION Clinical Trial Results (GlobeNewswire) +8.68%
Oct-20-22 04:30PM	Hepion Pharmaceuticals Announces Publication of Food Effect Study with Rencofilstat (GlobeNewswire)
Oct-19-22 08:00AM	Hepion Pharmaceuticals to Participate in the ThinkEquity Conference (GlobeNewswire)
Sep-26-22 05:00PM	Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology & HemeOnc Conference (GlobeNewswire) -6.06% +5.63%
Sep-14-22 08:00AM	Upcoming Presentation at Joint Meeting of ISBRA and ESBRA to Highlight Potential of Hepion Pharmaceuticals Rencofilstat to Treat Alcohol-Related Liver Disease (GlobeNewswire)
Sep-12-22 08:00AM	Hepion Pharmaceuticals Announces Initiation of Dosing in Phase 2 ALTITUDE-NASH Liver Function Trial (GlobeNewswire)
Sep-08-22 08:00AM	Hepion Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-31-22 08:00AM	Hepion Pharmaceuticals Announces Initiation of Phase 2b ASCEND-NASH Trial (GlobeNewswire)
Jul-22-22 04:15PM	Hepion Pharmaceuticals Announces Further Adjournment of Annual Meeting of Stockholders (GlobeNewswire)
Jul-04-22 10:23AM	We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate (Simply Wall St.)
Jun-28-22 08:30AM	Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati (GlobeNewswire)
Jun-24-22 04:15PM	Hepion Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders (GlobeNewswire)
Jun-20-22 08:00AM	Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma (GlobeNewswire)
Jun-15-22 08:00AM	Hepion Pharmaceuticals to Present Five Posters at EASL International Liver Congress 2022 (GlobeNewswire)
Jun-14-22 08:00AM	Hepion Pharmaceuticals Appoints Accomplished Life Sciences Industry Veteran, Dr. Launa J. Aspeslet, as Chief Operating Officer (GlobeNewswire)
May-31-22 04:30PM	Hepion Pharmaceuticals Urges Shareholders to Vote FOR All Proposals Ahead of its Upcoming Annual Meeting (GlobeNewswire)
May-27-22 08:54AM	CORRECTING and REPLACING - Hepion Pharmaceuticals, Inc. (GlobeNewswire) +6.32%
08:00AM	Hepion Pharmaceuticals Highlights Upcoming Phase 2 Clinical Trials of Recofilstat at 5th Global NASH Congress (GlobeNewswire)
May-03-22 08:00AM	Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial (GlobeNewswire)
Mar-07-22 08:00AM	Hepion Pharmaceuticals to Present at the Q1 Investor Summit Conference (GlobeNewswire) -7.32%
Feb-15-22 08:00AM	Hepion Pharmaceuticals Appoints World-Renowned Hepatologist, Dr. Eddie C. Cheung, to Lead the Companys Strategic Medical Affairs in Asia (GlobeNewswire)
Feb-14-22 08:00AM	Hepion Pharmaceuticals to Present at BIO CEO & Investor Conference (GlobeNewswire)
Jan-26-22 08:00AM	Hepion Pharmaceuticals Rencofilstat, in Combination with an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer Study (GlobeNewswire)
Jan-12-22 08:00AM	Hepion Pharmaceuticals Announces Death of Director, Thomas Adams (GlobeNewswire)
Jan-06-22 04:15PM	Hepion Pharmaceuticals Announces USAN Selection of Rencofilstat as Nonproprietary Name for CRV431 (GlobeNewswire)
Jan-05-22 04:30PM	Hepion Pharmaceuticals Announces Participation in the H.C. Wainwright BioConnect Conference (GlobeNewswire)
08:30AM	Hepion Pharmaceuticals to Present Clinical Data at NASH-TAG Conference (GlobeNewswire)
Dec-21-21 08:00AM	Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer (GlobeNewswire)
Nov-30-21 08:00AM	Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH (GlobeNewswire)
Nov-16-21 08:45AM	Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study (GlobeNewswire)
Nov-10-21 08:00AM	Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021 (GlobeNewswire)
07:55AM	Anti-Cancer Mechanism of Hepion Pharmaceuticals CRV431 Highlighted in Scripps Research Institute Poster at AASLD, The Liver Meeting® 2021 (GlobeNewswire)
Nov-04-21 08:00AM	Hepion Pharmaceuticals Presents at the EquitiesIQ Q4 2021 Investor Forum (GlobeNewswire)
Nov-02-21 08:00AM	Hepion Pharmaceuticals to Present at the EquitiesIQ Q4 2021 Investor Forum (GlobeNewswire)
Oct-07-21 08:00AM	Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference (GlobeNewswire)
Sep-29-21 09:00AM	All Endpoints Met in Hepion Pharmaceuticals Drug-Drug Interaction Study with CRV431 (GlobeNewswire)
Sep-13-21 08:00AM	Additional Data from Hepion Pharmaceuticals Phase 2a AMBITION Trial Further Strengthens CRV431 Clinical Profile and Paves Way for Initiation of Phase 2b ASCEND-NASH Clinical Program (GlobeNewswire)
Sep-10-21 04:05PM	Hepion Pharmaceuticals Schedules Conference Call to Review Data from Phase 2a AMBITION Clinical Trial of CRV431 in NASH (GlobeNewswire)
Aug-15-21 05:50AM	Is Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Popular Amongst Institutions? (Simply Wall St.)
Jul-23-21 04:40PM	Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders (GlobeNewswire)
Jul-13-21 08:00AM	Hepion Pharmaceuticals Announces Positive Topline Data from Phase 2a AMBITION NASH Trial; All Primary Endpoints Achieved (GlobeNewswire) -15.27%
Jun-25-21 04:30PM	Hepion Pharmaceuticals Announces Adjournment of Annual Meeting (GlobeNewswire)
Jun-09-21 07:45AM	Hepion Pharmaceuticals to be Added to the Russell Microcap® Index (GlobeNewswire)
May-16-21 05:10AM	Hepion Pharmaceuticals (NASDAQ:HEPA) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
May-06-21 07:45AM	Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH (GlobeNewswire)
Apr-29-21 09:50AM	Hepion Pharmaceuticals Presents Machine Learning Learn and Confirm Modeling Strategy at 4th Global NASH Congress (GlobeNewswire)
Mar-23-21 07:15AM	DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceuticals Lead Drug, CRV431 (GlobeNewswire)
Mar-22-21 04:30PM	Hepion Pharmaceuticals Announces Presentation and Panel Participation at the Benzinga Global Biotech Small Cap Conference (GlobeNewswire)
Mar-11-21 07:30AM	Hepion Pharmaceuticals to Present on CRV431 and AI-POWR at NASH-TAG 2021 (ACCESSWIRE) +11.48%
Feb-18-21 04:30PM	Hepion Pharmaceuticals, Inc. Announces Closing of Public Offering (ACCESSWIRE) +5.00%
Feb-16-21 06:45AM	Hepion Pharmaceuticals Announces Pricing of Public Offering (GlobeNewswire) -25.25%
Feb-12-21 04:45PM	Hepion Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock (ACCESSWIRE)
Feb-10-21 07:30AM	Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer (ACCESSWIRE)
Feb-09-21 04:30PM	Hepion Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference (ACCESSWIRE)

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HEPA

Hepion Pharmaceuticals Inc

Upgrade your FINVIZ experience